Madhavan Ramesh, Jacobs Bradley S, Levine Steven R
Department of Neurology, Wayne State University School of Medicine, Detroit, MI, USA.
Neurol Res. 2002;24 Suppl 1:S27-32. doi: 10.1179/016164102101200005.
We reviewed the recent, major, therapeutic trials of intravenous thrombolytic therapy and ancrod for ischemic stroke. Randomized, controlled studies of acute ischemic stroke treatment were reviewed. Several post-FDA approval intravenous tPA studies were reviewed to understand the experience of this medication in practice. STAT trial was the major study using ancrod. Of multiple intravenous thrombolytic studies, the NINDS study of intravenous tPA was the only study to demonstrate a significantly higher percentage of patients with complete recovery or minimal deficit at three months. Studies in communities utilizing intravenous tPA for stroke illustrate the need for close adherence to the NINDS study protocol or else the risk of tPA use may exceed the benefits.
我们回顾了近期关于缺血性中风的静脉溶栓治疗和安克洛酶的主要治疗试验。对急性缺血性中风治疗的随机对照研究进行了回顾。审查了几项美国食品药品监督管理局（FDA）批准后的静脉注射组织型纤溶酶原激活剂（tPA）研究，以了解这种药物在实际应用中的情况。STAT试验是使用安克洛酶的主要研究。在多项静脉溶栓研究中，NINDS关于静脉注射tPA的研究是唯一一项表明在三个月时完全康复或轻度残疾的患者比例显著更高的研究。在社区中使用静脉注射tPA治疗中风的研究表明，需要严格遵守NINDS研究方案，否则使用tPA的风险可能超过益处。
